Huntington's disease, FDA and Drug
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...
An intellectually active lifestyle—in other words, the so-called cognitive reserve—has a protective effect on the progression and severity of the symptoms of motor, cognitive and psychiatric ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
News Medical on MSN9d
Heart medication may slow the progression of Huntington's diseaseResearch indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
MedPage Today on MSN10d
Beta-Blockers Tied to Delayed Huntington's Disease ProgressionThe disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may ...
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused ...
3d
William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
Hosted on MSN3d
uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More OptimisticShares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback